Paya Carlos V 4

What Happened

• Carlos V. Paya, a director of Vaxcyte, received awards on 2026-06-15 totaling 13,654 share-equivalents: 2,265 restricted stock units (RSUs) and 11,389 derivative units (awarded at $0.00). The awards were reported on a Form 4 filed 2026-06-16.
• These are grants (no cash paid). The RSUs and the derivative award vest over time and are not immediate open-market purchases or sales.

Key Details

• Transaction date: 2026-06-15; Filing date (Accession): 2026-06-16 (appears timely).
• Awards: 2,265 RSUs @ $0.00; 11,389 derivative units @ $0.00; total 13,654 units.
• Vesting: Both awards fully vest on the earlier of June 15, 2027 or the day before the next annual meeting, subject to acceleration and the reporting person's continued service.
• Deferral: The RSUs are deferred under the issuer’s Nonqualified RSU Deferral Program for non-employee directors — delivery is deferred until separation from service or a qualifying change in control.
• Derivative specifics: The 11,389 units are subject to monthly vesting (per footnote) and fully vest on the same schedule noted above.
• Shares owned after transaction: Not specified in this filing.

Context

• This is a typical equity compensation grant for a non-employee director, not an open-market purchase or sale. Such awards are common for director compensation and do not by themselves indicate buy/sell directional intent.
• Because delivery of the RSUs is deferred and vesting is time-based, the awards represent future potential ownership contingent on continued service (or a change in control).